The main objective of the Tumor Immunology Program is to investigate the immunologic interactions between the host and tumor and to translate these findings into novel clinical trials in patients with cancer. The Program's membership includes basic and clinical investigators from the Departments pf Surgery, Internal Medicine, Pediatrics, Radiology, Pathology, and Microbiology. In addition, the Program has established formal scientific and clinical interactions with the Breast Oncology, Leukemia/Lymphoma, Gastrointestinal Oncology, Childhood Cancers, Head and Neck, and Urological/Prostate Programs to investigate the elicitation of immune responses to these tumors and the use of immune- based therapies in these settings. The Tumor Immunology Program relies heavily on the functions of several Cores, including Biostatistics, Flow Cytometry, Molecular Biology and Protein Chemistry, Experimental Irradiation, Vector, Animal, and the Clinical Trials Office. The Program has also played a key organizational role in the new Immunological Monitoring Core and has initiated studies involving the new Microarray Core. The research component of the Program focuses on efforts to improve tumor immunotherapy by developing novel vaccine adoptive T cell, and gene therapy tumor immunotherapy by developing novel vaccine adoptive T cell, and gene therapy approaches through the use of well-defined in vivo animal models, in vitro tissue culture systems, and state-of-the-art immunologic assays. In addition, the Program's investigators are actively involved in studies of the induction and breaking of immune tolerance as well as actively involved in studies of the induction and breaking of immune tolerance as well as immune reconstitution following hematopoietic stem cell transplantation as critical areas in tumor immunology. By doing so, the basic research component of the Program focuses on efforts to improve cancer immunotherapy. The clinical research component actively enrolls advanced to improve cancer immunotherapy. The clinical research component actively enrolls advanced cancer patients in novel clinical trials as a direct outcome of Program. Current and planned future clinical trials include: the use of tumor-pulsed dendritic cells, recombinant vaccinia viruses, and gene-modified tumor cells in vaccine strategies; the adoptive transfer of immune effector T cells and gene-modified hematopoietic stem cells; and the systemic delivery of recombinant cytokines. In the area of education, the Program has spearheaded the formal establishment of a new Ph.D. degree granting Graduate Program in Immunology administered through the University of Michigan's Rackham Graduate School and the Medical School. This new graduate program is directed by the Tumor Immunology Program's current director (J. Mule) with additional oversight by an operating committee in which the majority of seats are currently held by members of the Tumor Immunology Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-15
Application #
6597028
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-06-01
Project End
2003-05-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Menghrajani, Kamal; Boonstra, Philip S; Mercer, Jessica A et al. (2018) Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Leuk Lymphoma :1-7
Xiong, Xiufang; Liu, Xia; Li, Haomin et al. (2018) Ribosomal protein S27-like regulates autophagy via the ?-TrCP-DEPTOR-mTORC1 axis. Cell Death Dis 9:1131
Nanba, Kazutaka; Omata, Kei; Else, Tobias et al. (2018) Targeted Molecular Characterization of Aldosterone-Producing Adenomas in White Americans. J Clin Endocrinol Metab 103:3869-3876
Yu, Lei; Jearawiriyapaisarn, Natee; Lee, Mary P et al. (2018) BAP1 regulation of the key adaptor protein NCoR1 is critical for ?-globin gene repression. Genes Dev 32:1537-1549
Hoban, Connor W; Beesley, Lauren J; Bellile, Emily L et al. (2018) Individualized outcome prognostication for patients with laryngeal cancer. Cancer 124:706-716
Maust, Joel D; Frankowski-McGregor, Christy L; Bankhead 3rd, Armand et al. (2018) Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers. Mol Cancer Ther 17:2495-2506
Arthur, Anna E; Goss, Amy M; Demark-Wahnefried, Wendy et al. (2018) Higher carbohydrate intake is associated with increased risk of all-cause and disease-specific mortality in head and neck cancer patients: results from a prospective cohort study. Int J Cancer 143:1105-1113
Valenciaga, Anisley; Saji, Motoyasu; Yu, Lianbo et al. (2018) Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight 3:
Akkina, Sarah R; Kim, Roderick Y; Stucken, Chaz L et al. (2018) Is There a Difference in Staging and Treatment of Head and Neck Squamous Cell Tumors Between Tertiary Care and Community-Based Institutions? Laryngoscope Investig Otolaryngol 3:290-295
Anwar, Talha; Arellano-Garcia, Caroline; Ropa, James et al. (2018) p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis. Nat Commun 9:2801

Showing the most recent 10 out of 1493 publications